Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management of malignant pleural effusions

T J Lynch1

  • 1Division of Clinical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston.

Chest
|April 1, 1993
PubMed
Summary

Malignant pleural effusions (MPEs) are common in advanced cancers. Bleomycin may be superior to other sclerosing agents for MPE control, with ongoing research into optimal treatments and new therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Butyrylcholinesterase: an enzyme antidote for cocaine intoxication.

Addiction biology·2016
Same author

Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2015
Same author

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Area of Science:

  • Oncology
  • Pulmonology
  • Thoracic Surgery

Background:

  • Malignant pleural effusions (MPEs) are a frequent complication of advanced cancers, especially lung and breast cancer.
  • MPEs arise from mechanisms like lymphatic obstruction and tumor cell spread.
  • Treatment decisions for MPEs depend on cancer type, stage, patient performance status, and comorbidities.

Purpose of the Study:

  • To review current and emerging therapeutic strategies for managing malignant pleural effusions.
  • To highlight the efficacy of different sclerosing agents and novel treatment modalities.

Main Methods:

  • Review of existing literature on MPE management.
  • Analysis of therapeutic approaches including thoracentesis, pleurectomy, tube thoracostomy with sclerotherapy, and thoracoscopy.
  • Consideration of ongoing research into biological and chemotherapeutic agents.

Main Results:

  • Tube thoracostomy with sclerosing agents is a common MPE treatment.
  • Bleomycin shows promise as a superior sclerosing agent based on recent trial data.
  • Video-assisted thoracoscopy offers a new diagnostic and therapeutic avenue for MPEs.

Conclusions:

  • Optimal MPE management requires individualized treatment strategies.
  • Further research is needed to establish the best drainage methods and sclerosing agents.
  • Investigational therapies, including biological and chemotherapeutic agents, represent future treatment directions for MPEs.

Related Experiment Videos